Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elevance Health, Inc. due to allegations of false and misleading statements regarding the company's financial health and Medicaid cost management [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $100,000 in Elevance between April 18, 2024, and October 16, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against Elevance, with a deadline of July 11, 2025, for investors to seek the role of lead plaintiff [2]. Group 2: Allegations Against Elevance - The complaint alleges that Elevance and its executives violated federal securities laws by making false statements and failing to disclose the true nature of rising Medicaid costs [4]. - On July 17, 2024, Elevance disclosed an expectation of increased second-half utilization in Medicaid, leading to a stock price decline of $32.21 per share, or 5.8% [5]. - Further revelations on October 17, 2024, indicated that Elevance missed consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, resulting in a stock price drop of $52.61 per share, or 10.6% [6]. Group 3: Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [7]. - Any member of the class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [7]. Group 4: Whistleblower Encouragement - Faruqi & Faruqi encourages individuals with information regarding Elevance's conduct, including whistleblowers and former employees, to come forward [8].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits and financial disclosures [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors have until July 11, 2025, to request to be appointed to lead the case [2]. Group 2: Background on Elevance Health - Elevance Health provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused Medicaid eligibility reviews during COVID, which resumed in 2023 [3]. Group 3: Allegations of Misrepresentation - Elevance allegedly misrepresented its monitoring of cost trends related to the Medicaid redetermination process and the adequacy of negotiated rates [4]. - The redetermination process reportedly led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. Group 4: Stock Performance and Financial Impact - Following a statement on July 17, 2024, regarding increased Medicaid utilization, Elevance's stock price fell by $32.21, nearly 6%, from $553.14 to $520.93 [6]. - On October 17, 2024, Elevance announced Q3 2024 results, missing EPS expectations by $1.33 (13.7%) due to elevated medical costs in its Medicaid business, leading to a further stock decline of $52.61, nearly 11%, from $496.96 to $444.35 [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elevance Health, Inc. due to allegations of violations of federal securities laws related to misleading statements about Medicaid cost trends and earnings guidance [3][5]. Group 1: Allegations and Legal Actions - The complaint alleges that Elevance and its executives made false and misleading statements regarding their monitoring of Medicaid cost trends and the adequacy of premium rates negotiated with states [5]. - The company acknowledged rising Medicaid expenses but assured investors that these were adequately reflected in their guidance for the year [5]. - A federal securities class action has been filed against Elevance, with a deadline of July 11, 2025, for investors to seek the role of lead plaintiff [3][9]. Group 2: Financial Impact and Stock Performance - On July 17, 2024, Elevance disclosed an expectation of increased second-half utilization in Medicaid, leading to a stock price decline of $32.21 per share, or 5.8% [6]. - Following the announcement of third-quarter financial results on October 17, 2024, Elevance missed consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business [7]. - The company subsequently lowered its EPS guidance for 2024 from $37.20 to $33.00, or 11.3%, resulting in a further stock price decline of $52.61 per share, or 10.6% [8].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 11, 2025, to request to be appointed to lead the case [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits, which were paused during COVID-19 but resumed in 2023 [3]. - During the relevant period, Elevance claimed to be closely monitoring cost trends associated with the Medicaid redetermination process [4]. Group 3: Allegations and Financial Impact - Allegations state that the redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's rate negotiations or financial guidance for 2024 [5]. - Following the announcement of increased Medicaid utilization on July 17, 2024, Elevance's stock price fell by $32.21 per share, nearly 6%, from $553.14 to $520.93 [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61 per share, nearly 11%, from $496.96 to $444.35 [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Elevance Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2] Group 1: Class Action Details - The Class Period for the Elevance Health, Inc. stock purchase is from April 18, 2024, to October 16, 2024 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A lead plaintiff must file a motion with the Court by July 11, 2025, to represent other class members [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors [3] Group 3: Case Allegations - The lawsuit alleges that Elevance Health made false or misleading statements regarding the Medicaid redetermination process and its impact on financial guidance [4] - It is claimed that the acuity and utilization of Medicaid members increased significantly, contrary to the company's assurances to investors [4] - The misrepresentation of the Medicaid situation led to investor damages when the true details became public [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elevance Health, Inc. due to allegations of false and misleading statements regarding the company's financial health and Medicaid cost management [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Elevance between April 18, 2024, and October 16, 2024, to discuss their legal options [1]. - A federal securities class action has been filed against Elevance, with a deadline of July 11, 2025, for investors to seek the role of lead plaintiff [2]. Group 2: Allegations Against Elevance - The complaint alleges that Elevance and its executives violated federal securities laws by making false statements about their monitoring of cost trends and the adequacy of premium rates for Medicaid patients [4]. - The company acknowledged rising Medicaid expenses but assured investors that these were adequately reflected in their guidance for the year [4]. Group 3: Stock Price Impact - Following the disclosure on July 17, 2024, regarding increased Medicaid utilization, Elevance's stock price fell by $32.21 per share, or 5.8% [5]. - On October 17, 2024, Elevance reported third-quarter earnings that missed consensus EPS expectations by $1.33, or 13.7%, and lowered its EPS guidance for 2024 from $37.20 to $33.00, causing a further decline in stock price by $52.61 per share, or 10.6% [6].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits and the subsequent financial impact on the company [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, titled Miller v. Elevance Health, Inc., et al., No. 25-cv-0092, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 11, 2025, to request to be appointed to lead the case [2]. Group 2: Company Operations and Allegations - Elevance Health provides health insurance plans, including contracts with states to administer Medicaid benefits, which were paused during COVID-19 and resumed in 2023 [3]. - The company claimed to be monitoring cost trends related to Medicaid redetermination and believed its negotiated rates were adequate for the risk profiles of Medicaid patients [4]. Group 3: Financial Impact and Stock Performance - The redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. - Following an announcement on July 17, 2024, regarding increased Medicaid utilization, Elevance's stock price fell by $32.21, nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61, nearly 11%, from $496.96 to $444.35 per share [7].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits and financial disclosures [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may have until July 11, 2025, to request to lead the case [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused the Medicaid eligibility review process during COVID, which resumed in 2023, leading to increased scrutiny of Medicaid members [3]. Group 3: Financial Implications - Elevance claimed to be monitoring cost trends related to the Medicaid redetermination process and believed their negotiated rates were adequate for the risk profiles of Medicaid patients [4]. - However, the redetermination process resulted in a significant increase in the acuity and utilization of Medicaid members, which was not reflected in Elevance's financial guidance for 2024 [5]. Group 4: Stock Performance - Following Elevance's announcement on July 17, 2024, regarding increased Medicaid utilization, the stock price fell by $32.21, or nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, leading to a further decline of $52.61, or nearly 11%, in stock price from $496.96 to $444.35 per share [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elevance Health, Inc. due to allegations of violations of federal securities laws related to misleading statements about Medicaid cost trends and earnings guidance [3][5]. Group 1: Allegations and Legal Actions - The complaint alleges that Elevance and its executives made false or misleading statements regarding their monitoring of Medicaid cost trends and the adequacy of premium rates negotiated with states [5]. - A federal securities class action has been filed against Elevance, with a deadline of July 11, 2025, for investors to seek the role of lead plaintiff [3][9]. - The firm encourages investors who suffered losses in Elevance to contact them for discussions about their legal rights [1][10]. Group 2: Financial Impact and Stock Performance - On July 17, 2024, Elevance disclosed an expectation of increased Medicaid utilization, leading to a stock price decline of $32.21 per share, or 5.8% [6]. - Following the announcement of third-quarter financial results on October 17, 2024, Elevance missed EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business [7]. - The company subsequently lowered its EPS guidance for 2024 from $37.20 to $33.00, or 11.3%, resulting in a further stock price decline of $52.61 per share, or 10.6% [8].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to misleading statements about Medicaid cost trends and financial guidance [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may request to be appointed to lead the case by July 11, 2025 [2]. Group 2: Background on Medicaid and Elevance - Elevance provides health insurance plans, including Medicaid benefits, which were subject to a review pause during COVID-19 that ended in 2023 [3]. - The company claimed to be monitoring cost trends related to the Medicaid redetermination process and believed its negotiated rates were adequate for the risk profiles of Medicaid patients [4]. Group 3: Allegations and Financial Impact - Allegations state that the redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. - Following a statement on July 17, 2024, regarding increased Medicaid utilization, Elevance's stock price fell by $32.21, nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61, nearly 11%, from $496.96 to $444.35 per share [7].